FMP
Zosano Pharma Corporation
ZSAN
NASDAQ
Inactive Equity
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. On June 1, 2022, Zosano Pharma Corporation filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
0.558 USD
0 (0%)
Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
-
-
-
-
-
-
-
-
-
-
Revenue %
-
-
-
-
-
-
-
-
-
Operating Cash Flow
-7.68M
-11.85M
-15.62M
-18.86M
-16.84M
-
-
-
-
-
Operating Cash Flow %
100
100
100
100
100
100
100
100
100
Cap Ex
-180.29k
-367.89k
-115k
-33k
-37k
-
-
-
-
-
Cap Ex %
100
100
100
100
100
-
-
-
-
Free Cash Flow
-7.86M
-12.21M
-15.73M
-18.89M
-16.88M
-
-
-
-
-
Weighted Average Cost Of Capital
Price
2.91
Beta
Diluted Shares Outstanding
17.14M
Costof Debt
4.09
Tax Rate
After Tax Cost Of Debt
4.09
Risk Free Rate
Market Risk Premium
Cost Of Equity
Total Debt
1.06M
Total Equity
49.88M
Total Capital
50.95M
Debt Weighting
2.09
Equity Weighting
97.91
Wacc
10.49
Build Up Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
-
-
-
-
-
-
-
-
-
-
Operating Cash Flow
-7.68M
-11.85M
-15.62M
-18.86M
-16.84M
-
-
-
-
-
Cap Ex
-180.29k
-367.89k
-115k
-33k
-37k
-
-
-
-
-
Free Cash Flow
-7.86M
-12.21M
-15.73M
-18.89M
-16.88M
-
-
-
-
-
Wacc
10.49
10.49
10.49
10.49
10.49
Pv Lfcf
-
-
-
-
-
Sum Pv Lfcf
-
Terminal Value
Growth In Perpetuity Method
Long Term Growth Rate
Wacc
10.49
Free Cash Flow T1
0
Terminal Value
0
Present Terminal Value
0
Intrinsic Value
Enterprise Value
0
Net Debt
-690k
Equity Value
690k
Diluted Shares Outstanding
17.14M
Equity Value Per Share
0.04
Projected DCF
0.04025201 -71.295%
